Percentage of all primary or metastatic colorectal carcinoma surgical pathology reports that address the status of biomarker evaluation for mismatch repair (MMR) by immunohistochemistry (biomarkers MLH1, MSH2, MSH6 and PMS2), or microsatellite instability (MSI) by DNA-based testing status, or both. INSTRUCTIONS: This measure is to be reported each time a primary or metastatic colorectal carcinoma pathology report is finalized during the performance period. This measure may be submitted by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. The results of MMR/MSI testing of a sample are frequently needed at some point during a patient’s treatment. Pathologists are uniquely well positioned at the time of signing out the surgical pathology report to detail the disposition of MMR/MSI testing for that sample. Referring physicians depend on both the pathologists’ interpretations of and any recommendations for tests in order to provide quality patient care. If the status is not indicated in each pathology report for the patient, important tests may be missed or unnecessary repeat testing may be performed delaying treatment and increasing cost. This measure monitors the success of pathologists in effectively communicating this important information for the purpose of care coordination and efficient use of resources.